Ser580

Site Information
PVIsVktsGsKERAs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 18015374

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:	cervical cancer ( 6 ) , cervical adenocarcinoma ( 6 ) , leukemia ( 3 ) , acute myelogenous leukemia ( 3 ) , lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 5 ) , HeLa S3 (cervical) ( 6 ) , Jurkat (T lymphocyte) ( 4 ) , K562 (erythroid) ( 2 ) , KG-1 (myeloid) ( 3 ) , lung ( 1 )

Upstream Regulation
Treatments:	nocodazole ( 6 )

References
1	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
2	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
3	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
4	Zhou J (2011) CST Curation Set: 12496; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
5	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
6	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info